You are being directed to ZacksTrade, a division of Zacks & Company and licensed broker-dealer. ZacksTrade and Zacks.com are separate but affiliated companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 12/26/2014

Company Name Symbol %Change
ONCOLYTICS B ONCY
19.28%
PLANAR SYSTE PLNR
16.19%
AMBARELLA IN AMBA
7.47%
AGENUS INC AGEN
7.27%
CHINA LIFE I LFC
7.02%
Myriad Genetics (MYGN) Trading Near $28.44 Resistance Level

Print Share

Dec 12, 2012 (Marketintelligencecenter.com via COMTEX) -- Myriad Genetics (NASDAQ:MYGN) closed Tuesday's trading session at $27.81. In the past year, the stock has hit a 52-week low of $19.21 and 52-week high of $31.80. Myriad Genetics (MYGN) stock has been showing support around $27.12 and resistance in the $28.44 range. Technical indicators for the stock are Bearish. For a hedged play on Myriad Genetics (MYGN), look at the Feb '13 $26.00 covered call for a net debit in the $24.96 area. That is also the break-even stock price for this trade. This covered call has a duration of 66 days, provides 10.25% downside protection and an assigned return rate of 4.17% for an annualized return rate of 23.04% (for comparison purposes only). Myriad Genetics (MYGN) has a current trailing average dividend yield of 0%.

MarketIntelligenceCenter.com

(C) Copyright 2012, Marketintelligencecenter.com. All rights reserved.

Free Stock Analysis From Zacks

Includes Zacks Long-Term Recommendation and Target Price

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.